Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Abeta42 reduces their differentiation potential.
BACKGROUND
Alzheimer's disease (AD) is characterized by neurodegeneration and changes in cellular processes, including neurogenesis. Proteolytic processing of the amyloid precursor protein (APP) plays a central role in AD. Owing to varying APP processing, several beta-amyloid peptides (Abeta) are generated. In contrast to the form with 40 amino acids (Abeta40), the variant with 42 amino acids (Abeta42) is thought to be the pathogenic form triggering the pathological cascade in AD. While total-Abeta effects have been studied extensively, little is known about specific genome-wide effects triggered by Abeta42 or Abeta40 derived from their direct precursor C99.


METHODS
A combined transcriptomics/proteomics analysis was performed to measure the effects of intracellularly generated Abeta peptides in human neuroblastoma cells. Data was validated by real-time polymerase chain reaction (real-time PCR) and a functional validation was carried out using RNA interference.


RESULTS
Here we studied the transcriptomic and proteomic responses to increased or decreased Abeta42 and Abeta40 levels generated in human neuroblastoma cells. Genome-wide expression profiles (Affymetrix) and proteomic approaches were combined to analyze the cellular response to the changed Abeta42- and Abeta40-levels. The cells responded to this challenge with significant changes in their expression pattern. We identified several dysregulated genes and proteins, but only the cellular retinoic acid binding protein 1 (CRABP1) was up-regulated exclusively in cells expressing an increased Abeta42/Abeta40 ratio. This consequently reduced all-trans retinoic acid (RA)-induced differentiation, validated by CRABP1 knock down, which led to recovery of the cellular response to RA treatment and cellular sprouting under physiological RA concentrations. Importantly, this effect was specific to the AD typical increase in the Abeta42/Abeta40 ratio, whereas a decreased ratio did not result in up-regulation of CRABP1.


CONCLUSIONS
We conclude that increasing the Abeta42/Abeta40 ratio up-regulates CRABP1, which in turn reduces the differentiation potential of the human neuroblastoma cell line SH-SY5Y, but increases cell proliferation. This work might contribute to the better understanding of AD neurogenesis, currently a controversial topic.
Uhrig
Markus
M
Center for Molecular Biology of the University of Heidelberg, Heidelberg, Germany. m.uhrig@zmbh.uni-heidelberg.de
Brechlin
Peter
P
Jahn
Olaf
O
Knyazev
Yuri
Y
Weninger
Annette
A
Busia
Laura
L
Honarnejad
Kamran
K
Otto
Markus
M
Hartmann
Tobias
T
D016229:Amyloid beta-Peptides / Q000378:metabolism*; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D020869:Gene Expression Profiling; D055785:Gene Knockdown Techniques; D006801:Humans; D009474:Neurons / Q000378:metabolism* / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis; D010446:Peptide Fragments / Q000378:metabolism*; D020543:Proteome / Q000032:analysis; D018168:Receptors, Retinoic Acid / Q000096:biosynthesis* / Q000235:genetics; D015854:Up-Regulation
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; D020543:Proteome; D018168:Receptors, Retinoic Acid; C075222:amyloid beta-protein (1-42); C082927:retinoic acid binding protein I, cellular